Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...

GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

The global Apheresis Equipment Market is valued at $2.01 million in 2023 and is projected to reach a value of $2.20 million ...

The global Embolic Protection Devices Market is valued at $601 million in 2023 and is projected to reach $1,250 million by ...

Foster City, California Thursday, February 20, 2025, 12:00 Hrs [IST] ...

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

Finasteride and Minoxidil, used to treat baldness, can also cause erectile dysfunction and serious impairment of energy ...

Medical Packaging Market Key market drivers include rising healthcare expenditures, growing demand for medical devices & stringent regulato ...